Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
JK-P3 is an inhibitor of the tyrosine kinases VEGFR2, FGFR1, and FGFR3 (IC50s = 7.83, 27, and 5.18 µM, respectively).1 It decreases VEGF-A-induced VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVECs) when used at a concentration 10 µM. JK-P3 decreases the proliferation of HCT116, SW480, and HT-29 colon cancer cells (IC50s = 24.26, 27.2, and 29.65 µM, respectively), as well as A549 lung cancer cells (IC50 = 30.49 µM).2 It decreases wound closure percentage in a scratch assay, as well as endothelial branch length and branch points formed by VEGF-A-stimulated HUVECs when used at a concentration of 10 µM.1
WARNING This product is not for human or veterinary use.
1. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br. J. Pharmacol. 166(2), 737-748 (2012).
2. Discovery of 2-